The Mexican consensus [4] and clinical practice guidelines for breast cancer [5–7], the main working documents for oncologists in the country, recommend routine use of a 3-marker panel (ER, PR, HER2) to guide management and treatment for patients. This evidence concerns the gene PGR and breast cancer.